Albireo Reports Q1 Financial Results and Business Update
– BylvayTM (odevixibat) commercial readiness on track for anticipated H2 21 launch in U.S. and EU–
– Completed global commercial agreements for two key top ten markets –
– ASSERT & BOLD Phase 3 studies enrolling and on track –
– Advanced novel MOA ASBTi A3907 into Phase 1